The study published in the NZMJ notes that the prescription rates had previously been rising since 2014. New Zealand rates were 1.7 times higher than the Netherlands by 2018, and 3.5-6.9 times higher than England and Wales up to 2020 – however there is no more recent international data to compare with NZ since prescribing rates began to drop in 2021.
This is a companion discussion topic for the original entry at https://www.sciencemediacentre.co.nz/2024/09/27/puberty-blocker-prescribing-rates-in-nz-expert-reaction/